⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 2, 2025Open Access

Supplementary Figure 6 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Kaushik Varadarajan Christian X. Cruz Pico Kurt W. Evans Maria Gabriela Raso Yasmeen Q. Rizvi Xiaofeng Zheng Dhruv Chachad Timothy P. DiPeri Bailiang Wang Stephen M. Scott Ming Zhao Argun Akçakanat Antje M. Wengner Timothy A. Yap Funda Meric‐Bernstam

View Full Paper

Ask AI

Bookmark

Share

Key Points

Elimusertib shows promising activity in tumors with DNA damage response alterations, indicating its potential therapeutic value.
In vivo testing revealed significant responses in PDX models, highlighting the drug's effectiveness against specific tumor types.
The study focuses on the role of ATR kinase inhibitors, particularly elimusertib, in treating genomic alterations in cancer.
These findings may pave the way for developing targeted therapies using elimusertib in oncology settings.

Implication

In vivo response to elimusertib treatment in tumors with genomic alterations, suggesting potential effectiveness.

Abstract

Supplementary Figure 6: In vivo response to elimusertib from pre-treatment biopsy PDX models.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varadarajan et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02888 https://doi.org/10.1158/1535-7163.30028660

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
2Supplementary Figure 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
3Supplementary Figure 9 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
4Supplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
5Supplementary Figure 7 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025